Association between brain-derived neurotrophic factor (BDNF) gene polymorphisms and executive function in Japanese patients with Alzheimer's disease.

Division of Molecular Genetics, Institute of DNA Medicine, Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan.
Psychogeriatrics (Impact Factor: 1.22). 09/2011; 11(3):141-9. DOI: 10.1111/j.1479-8301.2011.00364.x
Source: PubMed

ABSTRACT To address the functional roles of genetic polymorphisms of brain-derived neurotrophic factor (BDNF) in Alzheimer's disease (AD) from a neuropsychological aspect, we used a cross-sectional study design to investigate the association between novel single nucleotide polymorphisms (SNPs) of the BDNF gene (Val66Met (G196A) and C270T) and the Frontal Assessment Battery (FAB) score, which reflects executive function as a non-memory cognitive impairment.
One hundred and sixty-nine outpatients with AD or amnestic mild cognitive impairment (A-MCI) were recruited to the study and divided into three genotypic groups for each representative BDNF functional polymorphism as follows: (i) Val66Met (G196A): G/G (n = 45), G/A (n = 104), and A/A (n = 20); and (ii) C270T: C/C (n = 160), C/T (n = 9), and T/T (n = 0). Then, age, sex ratio, duration of illness (months), education years, Mini-Mental State Examination (MMSE) score, behavioral pathology in Alzheimer disease (Behave-AD) score, Clinical Dementia Rating (CDR) ratio, and total and subtest FAB scores were compared between the genotypic groups for each SNP.
Significant differences were found in the total (P < 0.01) and subtest (conflicting instructions and prehension behavior; P < 0.01) FAB scores between the C270T polymorphism groups (C/C and C/T), but not among the G196A polymorphism groups. However, no significant differences in age, sex ratio, duration of illness (months), education years, Behave-AD score, CDR ratio, or MMSE score (reflecting attention and memory function) were found between the individual polymorphism genotypes (G196A and C270T).
Of the known BDNF polymorphisms, the C270T SNP may influence executive dysfunction as a non-memory cognitive impairment in Japanese patients with AD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is accumulating evidence that neurotrophins, like brain-derived neurotrophic factor (BDNF), may impact aging and Alzheimer's Disease. However, traditional genetic association studies have not found a clear relationship between BDNF and AD. Our goal was to test whether BDNF single nucleotide polymorphisms (SNPs) impact Alzheimer's Disease-related brain imaging and cognitive markers of disease. We completed an imaging genetics study on 645 Alzheimer's Disease Neuroimaging Initiative participants (ND=175, MCI=316, AD=154) who had cognitive, brain imaging, and genetics data at baseline and a subset of those with brain imaging data at two years. Samples were genotyped using the Illumina Human610-Quad BeadChip. 13 SNPs in BDNF were identified in the dataset following quality control measures (rs6265(Val66Met), rs12273363, rs11030094, rs925946, rs1050187, rs2203877, rs11030104, rs11030108, rs10835211, rs7934165, rs908867, rs1491850, rs1157459). We analyzed a subgroup of 8 SNPs that were in low linkage disequilibrium with each other. Automated brain morphometric measures were available through ADNI investigators, and we analyzed baseline cognitive scores, hippocampal and whole brain volumes, and rates of hippocampal and whole brain atrophy and rates of change in the ADAS-Cog over one and two years. Three out of eight BDNF SNPs analyzed were significantly associated with measures of cognitive decline (rs1157659, rs11030094, rs11030108). No SNPs were significantly associated with baseline brain volume measures, however six SNPs were significantly associated with hippocampal and/or whole brain atrophy over two years (rs908867, rs11030094, rs6265, rs10501087, rs1157659, rs1491850). We also found an interaction between the BDNF Val66Met SNP and age with whole brain volume. Our imaging-genetics analysis in a large dataset suggests that while BDNF genetic variation is not specifically associated with a diagnosis of AD, it appears to play a role in AD-related brain neurodegeneration.
    PLoS ONE 09/2013; 8(9):e76001. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Analysis of Serum brain derived neurotrophic factor (BDNF) levels in Alzheimer's disease (AD), amnestic Mild Cognitive Impairement (aMCI) and controls with BDNF gene polymorphism and cognitive function were investigated. The study recruited 63 AD patients, 15 aMCI and 63 age and sex matched healthy controls from All India Institute of Medical Sciences, New Delhi, India. Patients with AD (12268.3 ± 7099.9 pg BDNF/ml) and aMCI(10780 ± 4184.2 pg BDNF/ml) had higher serum levels than controls (9362.833 ± 5883.32 pg BDNF/ml). Significant difference in BDNF levels were not found between the three groups. No significant difference was obtained between BDNF genotype and allele distribution between AD patients, aMCI vs controls; Genotypic frequency: Chi-square = 3.21; p-value = 0.20 and Allelic frequency: Chi-square = 0.412, p-value = 0.521, d.f = 1 (AD Vs controls); Chi-square = 1.63, p-value = 0.201, d.f = 1 (aMCI vs controls). In conclusion, val66met polymorphism and BDNF serum level between the three groups and genotype did not significantly affect the serum BDNF level or age, MMSE score in AD and aMCI. Further studies are necessary to elucidate the kinetics and the potential role of serum BDNF as a marker of disease progression in AD patients.
    The International journal of neuroscience 12/2012; · 1.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain Derived Neurotrophic Factor (BDNF) promotes neuronal survival during development and protects neurons from insults of various kinds. Changes in production of BDNF have been reported in differing neurodegenerative pathologies and in particular in Alzheimer's disease (AD). We studied BDNF Val66Met (G196A), BDNF 270 C/T and the BDNF 11757 G/C genomic polymorphisms in 200 Alzheimer patients and 408 healthy controls for BDNF Val/Met, 384 healthy controls for BDNF 270 C/T and 393 healthy controls for BDNF 11757 C/G by RFLP and RealTime PCR. Our results indicated that 11757 G/C BDNF polymorphism was significantly associated with AD: a statistically significant increase of GG genotype frequency in AD vs healthy subjects (p=0.0331) was observed; whereas the CG genotype demonstrates a statistically significant decrease of frequency in AD patients vs controls (p=0.0194). We focalized our attention on haplotype reconstruction: a statistically significant decrease of the TAC haplotype frequency in AD patients vs healthy controls group (p= 0.005) and a statistically significant increase of the CAC haplotype frequency in patients vs control (p=0.019) was demonstrated. We then studied the haplotype frequencies dividing patients according to gender. A statistically significant increase of CAC haplotype in male AD group compared with male healthy controls (p=0.041) was found, whereas a significant statistically decrease of TAC haplotype frequency in AD female vs healthy female (p=0.005) and a significant statistically increase of CAC haplotype frequency in female patients vs healthy female ( p=0.019) was noticed. We propose that these haplotypes could be a further effective marker for AD.
    Rejuvenation Research 12/2012; · 2.92 Impact Factor


Available from
Jun 2, 2014